Recruiting Confirmatory Study of Eteplirsen in DMD Patients Condition: Duchenne Muscular Dystrophy (DMD)
Intervention: Drug: eteplirsen injection
2 Recruiting Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy Condition: Muscular Dystrophy, Duchenne
Intervention: Drug: eteplirsen
What abbie did was so wrong and is fraud , gild just raised 4 billion to send them to the sidelines without using the other massive cash they have.. gild is one of the greatest companies of this time.
A law suit of any kind is worthless based on the fda pass through information and this Company is a Delaware corp........
investments ,cannot beat the easy long term gains here
you should research a bit more before those comments..ha
Myself these patents should stand alone like they are and be based only on the drug that is being used for exon skipping. Mechanisms of actions of the drug itself .like Sarepta would have pmo-s as their action for exon skipping and Prosena has their drug''different from Sarepta's '' exon skipping is a verb or a trademark .the drug of the action of the Patent should stand as what it is.
Collaborated with the Wellcome Trust, World Health Organization (WHO), and other international authorities in an important program funding clinical trials in West Africa for several experimental Ebola drugs, designed to accelerate the identification and delivery of potential life-saving treatments to those infected by the Ebola virus
sooner or later justice will be served ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Seems the FDA was buying time for some odd reason?I think what the FDA is trying to do is this.''linking the natural history change that is very clear to the evidence that caused this change..''they already had this but wants a complete circle.
and those dollar loses are so very near for shorts..I see a big upside coming..
Looks like it is worth about 16.50 a share,can anyone give me some background here.
11/03/2014 | 07:48am US/EasternSend by mail:
By Targeted News Service
ALEXANDRIA, Va., Nov. 3 -- Sarepta Therapeutics, Bothell, Washington, has been assigned a patent (8,871,918) developed by two co-inventors for "[m]ultiple exon skipping compositions for DMD." The co-inventors are Ryszard Kole, Bellevue, Washington, and Peter Sazani, Bothell, Washington.
The patent application was filed on Oct. 23, 2009 (12/605,276)
The short list of possible drugs includes ZMapp, which has been tried with a handful of patients in this outbreak, and an experimental drug made by a company called Tekmira, which was given to a medical worker with Ebola who was treated in Nebraska.
A third candidate is called AVI-7537, being developed by Sarepta Therapeutics in Cambridge, Mass. Sarepta started to develop this drug in 2010 under a contract with the U.S. military to work on drugs for Ebola and the closely related Marburg virus.
"The Ebola study got discontinued in late 2012 because of the fiscal budgetary issues in the United States at the time," says Dr. Michael Wong, senior medical director for infectious diseases at Sarepta.
Early tests showed the drug appeared safe in a small sample of people and fairly effective in treating monkeys with Ebola. But the budget cut stopped further tests.
Wong says there's enough of this potential drug for 25 patients to receive a full course of treatment, which should be sufficient for initial tests in West Africa. If those results are promising, the company has enough ingredients to make another 100 to 150 doses. But that's still a minuscule supply.
Sarepta would like to produce tens of thousands of doses in a matter of months. "That's the corporate goal," Wong says. But the company doesn't have funding to ramp up production on speculation that the drug will be effective. It's looking for funding but hasn't found it yet, Wong says.